 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH announces that the U.S. Food and Drug Administration FDA has approved the Guardant360 CDx test as the first and only liquid biopsy companion diagnostic for tumor mutation profiling, or comprehensive genomic profiling, to identify patients with locally advanced or metastatic non-small cell lung cancer NSCLC who harbor the KRAS G12C mutation and may benefit from LUMAKRASTM sotorasib, an FDA-approved KRASG12C inhibitor 